Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2009

View Archived Issues

Biocompatibles and AstraZeneca sign agreements for GLP-1 analogue

Cytokinetics retains rights to ispinesib and SB-743921

MediciNova issues proposal to acquire Avigen

Ligand completes acquisition of Pharmacopeia

Novartis and AlphaVax sign exclusive license agreement for CMV vaccines

Daiichi Sankyo enters vaccine alliance with The Kitasato Institute

LifeCycle commences LCP-Tacro phase III trials

BI-2536 active and well tolerated in elderly patients with relapsed/refractory AML

Nabi reaches agreement with FDA on SPA for a phase III clinical trial of NicVax

Sosei reacquires commercialization rights to opioid analgesic AD-923 from Mundipharma

Salix receives FDA complete response letter for balsalazide

Savient's pegloticase BLA for treatment-failure gout granted priority review

FDA issues complete response letter to Ipsen for Dysport BLA in cervical dystonia

Clinical benefit seen with INCB-018424 in myelofibrosis

Results reported for phase II study of SGN-40 in diffuse large B-cell lymphoma

Breast cancer progression may be inhibited by fluvastatin

King acquires Alpharma

FDA accepts for filing Northfield Laboratories' BLA for PolyHeme

GTx submits NDA for toremifene for bone fracture prevention in prostate cancer

Johnson & Johnson plans short-form merger of Omrix

Urigen amends licence agreement with UCSD for URG-101

Novel matrix metalloproteinase inhibitors from Array BioPharma

New chymase inhibitors for cardiovascular diseases patented at Boehringer Ingelheim

New mgluR2 ligands/5-HT2A antagonists described in Abbott patent

SARS DNA vaccine safe, immunogenic in phase I study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 6, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 6, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.